|
KMID : 1118520130100040417
|
|
Psychiatry Investigation
2013 Volume.10 No. 4 p.417 ~ p.420
|
|
|
Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases
|
|
Albayrak Yakup
Hashimoto Kenji
|
|
|
Abstract
|
|
|
|
Fluvoxamine is a selective serotonin reuptake inhibitor that is approved for psychiatric disorders such as major depressive episodes and obsessive-compulsive disorder. Beside inhibition of serotonin reuptake, fluvoxamine is also a potent agonist of endoplasmic reticulum (ER) protein sigma-1 receptors, which play a role in the pathophysiology of a number of psychiatric and neurodegenerative disorders. This report presents beneficial effects of sigma-1 agonist fluvoxamine on hyperkinetic movement disorders such as tardive dyskinesia and tardive akathisia. Fluvoxamine might be a novel treatmet approach in the treatment of hyperkinetic movement disorders.
|
|
|
KEYWORD
|
|
|
Sigma receptor, Fluvoxamine, Akathisia, Dyskinesia
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|